

Practitioner's Docket No. **MBIO99-030RCEM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Barnes, Thomas M., et al. (as amended)		
Application No.:	09/333,159	Group No.:	1646
Filed:	June 14, 1999	Examiner:	Jiang, Dong
For:	NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES		

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Supplemental Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and PTO/SB/08B (5 pages)
3. ☒ Copies of Listed Information Items Accompanying This Statement (29 references)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV407386695US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Date: January 9, 2004

Carolyn Willey
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

01/13/2004 EFLORES 00000057 501668 09333159

01 FC:1806 180.00 DA

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement. Please note that these references and Information Disclosure Statement were previously submitted to the Examiner on December 21, 1999, and on November 19, 2002, however only the PTO-1449 form was received by the Examiner and not the references.

January 9, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone – (617) 679-7336

Facsimile – (617) 551-8820

Practitioner's Docket No. MBIO99-030RCEM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Barnes, Thomas M., et al. (as amended)		
Application No.:	09/333,159	Group No.:	1646
Filed:	June 14, 1999	Examiner:	Jiang, Dong
For:	NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES		

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

☐ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV407386695US

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Carolyn Willey
Signature

Date: January 9, 2004

Carolyn Willey
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" *must* have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket N . MBIO99-030RCEM

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☒ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☒ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☒ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MBIO99-030RCM

FEE PAYMENT


3. ☒ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☐ Applicant believes no fee is due in connection with this submission.

		Fee due	\$180.00
METHOD OF PAYMENT OF FEE			
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.			
<input checked="" type="checkbox"/> Charge Account No. 501668 in the amount of		\$180.00	.

☒ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>January 9, 2004</u>	MILLENNIUM PHARMACEUTICALS, INC. By  Jean M. Silveri Registration No. 39,030 75 Sidney Street Cambridge, MA 02139 Telephone – (617) 679-7336 Facsimile – (617) 551-8820
------------------------	--

+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION
STAT
JAN 09 2004
Sheet
PATENT & TRADEMARK OFFICE

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	09/333,159
Filing Date	June 14, 1999
First Named Inventor	Barnes, Thomas M., et al. (as amended)
Group Art Unit	1646
Examiner Name	Jiang, Dong
Attorney Docket Number	MBIO99-030RCEM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C1	ELSBACH, P., "The Bactericidal/Permeability-Increasing Protein (BPI) in Antibacterial Host Defense", <i>Journal of Leukocyte Biology</i> , Vol.64, July 1998, pp.14-18	
	C2	MAHADEVA, R. MD, et al. "Vasculitis and Bronchiectasis in a Patient With Antibodies to Bactericidal/Permeability-Increasing Protein and alpha sub 1-Antitrypsin Deficiency", <i>CHEST</i> , Vol. 112(6), December 1997, pp. 1699-1701	
	C3	DOCHERTY, A.J., et al. "Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL) (Lingual lipase)", Created August 13, 1987, (sequence) GenPept (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. P04634.	
	C4	Vaganay, S., et al. "Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)", Sequence updated July 15, 1998, (sequence) GenPept (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. P80035.	
	C5	Bodner, M. W., et al. "Triacylglycerol lipase, gastric precursor (Gastric lipase) (GL)", Created April 1, 1988, (sequence) GenPept (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. P07098.	
	C6	Anderson, R. A., et al. "Lysosomal acid lipase/cholesteryl ester hydrolase precursor (LAL) (Acid cholesteryl ester hydrolase) (Sterol esterase) (Lipase A) (Cholesteryl esterase)", Sequence updated October 1, 1994, (sequence) GenPept (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. P38571.	
	C7	Waterston, R. "Hypothetical protein C06E1.3 in chromosome III", Created February 1, 1994, (sequence) GenPept (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. P34298.	
	C8	Strausberg, Robert. "Homo sapiens cDNA clone", June 25, 1997, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenPept Accession No. AA506741.	
	C9	Marra, M. "Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone", November 25, 1997, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA670682.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Application Number

09/333,159

Filing Date

June 14, 1999

First Named InventorBarnes, Thomas M., et al.
(as amended)**Group Art Unit**

1646

Examiner Name

Jiang, Dong

Attorney Docket Number

MBIO99-030RCEM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C10	Marra, M., et al., "vi87g10.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone IMAGE:919266 5', MRNA sequence", July 1, 1997, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA499001.	
	C11	Marra, M., et al., "vu67d08.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone IMAGE:1196463 5', MRNA sequence", February 9, 1998, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA794194.	
	C12	Marra, M., et al., "vv53h10.r1 Soares_thymus_2NbMT Mus musculus cDNA clone IMAGE:1226179 5', MRNA sequence", January 21, 1998, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA756504.	
	C13	McIaren, S., "Human DNA sequence from clone CTA-57G9 on chromosome 22q12.1, complete sequence." June 3, 2003, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA295116.	
	C14	Wijngaard, P. L., et al., "B.bovis WC1.1 mRNA", May 24, 1994, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. X63723.	
	C15	Puschel, A. W., et al., "M. musculus mRNA for semaphoring B.", July 8, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. X85991.	
	C16	Strausberg, R. Ph.D., "aa34h11.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:815205 5', MRNA sequence", June 23, 1997, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA481246.	
	C17	Wilson, R. K., "ze94e06.r1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:366658 5', MRNA sequence", March 29, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA029404.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

Application Number

09/333,159

Filing Date

June 14, 1999

First Named InventorBarnes, Thomas M., et al.
(as amended)**Group Art Unit**

1646

Examiner Name

Jiang, Dong

Attorney Docket Number

MBIO99-030RCEM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C18	Nathans, J., "17e7 Human retina cDNA randomly primed sublibrary Homo sapiens cDNA, MRNA sequence", May 8, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. W25986.	
	C19	Wilson, R. K., et al., "zj63a09.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:454936 3', MRNA sequence", February 5, 1998, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA779337.	
	C20	Wilson, R. K., et al., "zn42f02.r1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone IMAGE:550107 5', MRNA sequence", November 27, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA082143.	
	C21	Marra, M., et al., "me11b04.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:387151 5', MRNA sequence", June 11, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. W65734.	
	C22	Marra, M., et al., "mj65c04.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone IMAGE:480966 5', MRNA sequence", September 23, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA059511.	
	C23	Marra, M., et al., "mq60d04.r1 Soares_thymus_2NbMT Mus musculus cDNA clone IMAGE:583111 5', MRNA sequence", December 11, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AA153748.	
	C24	Smith, M., "Human DNA sequence from clone RP1-149A16 on chromosome 22, complete sequence.", March 4, 2003, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. AL021937.	
	C25	Ameis, D. et al., "H.sapiens mRNA for lysosomal acid lipase", February 25, 1994, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ . GenBank Accession No. X76488.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Applicati n Numb r	09/333,159
Filing Date	June 14, 1999
First Named Invent r	Barnes, Thomas M., et al. (as amended)
Group Art Unit	1646
Examiner Name	Jiang, Dong
Attorney Docket Number	MBIO99-030RCEM

Sheet of 4

(use as many sheets as necessary)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T ²
	C26	Wilson, R. K., "zd90g02.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:356786 3', MRNA sequence", June 19, 1996, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ >. GenBank Accession No. W80832.	
	C27	Wilson, R. K., "ab94f09.s1 Stratagene lung (#937210) Homo sapiens cDNA clone IMAGE:854633 3', MRNA sequence", June 25, 1997, (sequence) GenBank (online) Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on January 7, 2004]. Retrieved from the Internet: URL: http://www.ncbi.nlm.gov/ >. GenBank Accession No. AA630445.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includ copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.